Home Featured Page 230

Featured

Latest

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

PT270 – Dr. Rachel Yehuda – Research Trials and The Future...

Complete Results from Red Light Oregon Market Research in Oregon Show...

Cybin Granted DEA Schedule I Manufacturing License

MINDCURE Provides Update on Studies and Clinical Trials

The Missing Mushroom: Psychedelic Science and the Future of Psilocybin

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy...

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker...

Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion...

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development...

Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully...

EDITOR PICKS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

PT270 – Dr. Rachel Yehuda – Research Trials and The Future...

Complete Results from Red Light Oregon Market Research in Oregon Show...

Cybin Granted DEA Schedule I Manufacturing License

MINDCURE Provides Update on Studies and Clinical Trials

The Missing Mushroom: Psychedelic Science and the Future of Psilocybin

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy...

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker...

Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion...

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development...

Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully...

EDITOR PICKS

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY